NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Zacks12-23 23:00

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493767544?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","is_english":true,"pubTime":"2024-12-23 23:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493767544","market":"us","top_or_hot":-1,"title":"NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III","media":"Zacks","content":"<div>\n<p>Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/nvo-stock-plunges-obesity-drug-150000998.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/nvo-stock-plunges-obesity-drug-150000998.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/nvo-stock-plunges-obesity-drug-150000998.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://finance.yahoo.com/news/nvo-stock-plunges-obesity-drug-150000998.html","article_id":"2493767544","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493767544","pubTimestamp":1734966000,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Novo NordiskNVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68compared to placebo.CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness and helping individuals consume fewer calories.Analysis of the phase III REDEFINE 1 study data after 68 weeks, assuming all people adhered to treatment, revealed that a superior weight loss of 22.7% was achieved with CagriSemacompared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with Wegovy and 2.3% with placebo alone. Additionally, Novo Nordisk reported that 40.4% of patients who received CagriSema after 68 weeks achieved a weight loss of 25% or more, compared to 6% with cagrilintide 2.4 mg, 16.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东","LLY":"礼来","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","III":"信息服务","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4585":"ETF&股票定投概念","LU0238689110.USD":"贝莱德环球动力股票基金","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4559":"巴菲特持仓","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4588":"碎股","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4134":"信息科技咨询与其它服务","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","NVO":"诺和诺德","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","AMGN":"安进"},"translate_title":"由于肥胖药物CagriSema未达到III期目标，NVO股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"NVO":1,"MRK":1,"III":1,"LLY":0.9},"content_text":"Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68 compared to placebo.\nCagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness and helping individuals consume fewer calories.\nAnalysis of the phase III REDEFINE 1 study data after 68 weeks, assuming all people adhered to treatment, revealed that a superior weight loss of 22.7% was achieved with CagriSema compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with Wegovy and 2.3% with placebo alone. Additionally, Novo Nordisk reported that 40.4% of patients who received CagriSema after 68 weeks achieved a weight loss of 25% or more, compared to 6% with cagrilintide 2.4 mg, 16.2% with Wegovy and 0.9% with placebo.\nDespite the positive results, Novo Nordisk’s shares plunged 17.8% as the 22.7% weight loss, observed in patients treated with CagriSema in the phase III REDEFINE 1 study, failed to meet the company’s guidance for 25% weight loss at week 68, which was provided on the third-quarter earnings call.\nIn the past three months, shares of Novo Nordisk have lost 32.2% compared with the industry’s 17.4% decline.\nImage Source: Zacks Investment Research\nAdditionally, analysis of the study data regardless of treatment adherence showed that patients treated with CagriSema achieved a superior weight loss of 20.4% compared to a reduction of 11.5% with cagrilintide 2.4 mg, 14.9% with Wegovy and 3% with placebo. In the REDEFINE 1 study, CagriSema, cagrilintide 2.4 mg and Wegovy were all well-tolerated and demonstrated an acceptable safety profile. Adverse events related to treatment with CagriSema were mostly gastrointestinal, which were mild to moderate in severity.\nNovo Nordisk is currently evaluating CagriSema in four ongoing phase III studies under the REDEFINE Program for obesity or overweight, including the REDEFINE 1 study. Top-line data readout from the second pivotal phase III REDEFINE 2 study, in adults with type 2 diabetes (T2D) and either obesity or overweight, is anticipated during the first half of 2025.\n\nNovo Nordisk A/S Price and Consensus\n\nNovo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote\n\nCompetition Heating Up in Obesity Space\nFollowing the news, shares of Novo Nordisk’s archrival in the obesity market space, Eli Lilly LLY, gained as its marketed drug, Zepbound (tirzepatide), continues to maintain the best-in-class title for obesity treatment. The highest dose of Zepbound has shown 25% weight loss over a similar duration in a late-stage study, compared to 22.7% with CagriSema. As a result, investors are now skeptical about whether NVO’s head-to-head phase III REDEFINE 4 study will be able to demonstrate the superiority of CagriSema over Zepbound 15 mg at week 72. Tirzepatide is a dual GIP and GLP-1 receptor agonist. LLY also markets tirzepatide as Mounjaro for T2D.\nRecently, the FDA removed Lilly’s tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future. This also provides a huge competitive edge to Lilly over Novo Nordisk, whose semaglutide medicines, Ozempic (for T2D) and Wegovy, remain on that list. Earlier this month, Lilly announced that Zepbound outperformed NVO’s Wegovy (20.2% compared to 13.7%, respectively) in a weight-loss head-to-head study. Such efficacy data bodes well for LLY and can help drive market share and potentially establish the drug as the new standard for obesity medications.\nNVO’s underwhelming data readout also stands to benefit Amgen AMGN, which is developing its weight-loss candidate, MariTide, in a mid-stage study. Unlike CagriSema, which delivered 22.7% weight loss over 68 weeks, AMGN’s MariTide achieved an impressive 20% average weight loss in just 52 weeks, with no signs of a weight loss plateau — suggesting even greater potential with a longer study duration. Additionally, MariTide’s once-monthly dosing regimen offers a significant advantage by reducing treatment burden, which could enhance patient compliance and make it a more attractive option if efficacy remains competitive.\nMerck MRK recently forayed into the obesity market, announcing plans to in-license global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma. Oral pills like HS-10535, if approved as weight loss drugs, can significantly improve patients’ convenience and potentially their costs. For the exclusive global rights, Merck will make an upfront payment of $112 million to Hansoh Pharma, with the latter also being entitled to receive up to $1.9 billion in milestone payments and royalties on sales. Hansoh has an option to co-promote or solely commercialize HS-10535 in China.\nNVO’s Zacks Rank\nNovo Nordisk currently carries a Zacks Rank #3 (Hold).\nYou can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nMerck & Co., Inc. (MRK) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nAmgen Inc. (AMGN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493767544"}